Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. H. Lundbeck A/S
  6. Summary
    LUN   DK0010287234

H. LUNDBECK A/S

(LUN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
07/21/2021 07/22/2021 07/23/2021 07/26/2021 07/27/2021 Date
192.45(c) 195(c) 190.25(c) 190.05(c) 188.3 Last
290 911 362 746 599 155 364 295 340 244 Volume
+0.26% +1.33% -2.44% -0.11% -0.92% Change
More quotes
Estimated financial data (e)
Sales 2021 16 626 M 2 642 M 2 642 M
Net income 2021 1 484 M 236 M 236 M
Net Debt 2021 2 283 M 363 M 363 M
P/E ratio 2021 27,4x
Yield 2021 1,69%
Sales 2022 17 693 M 2 812 M 2 812 M
Net income 2022 1 987 M 316 M 316 M
Net cash position 2022 132 M 21,0 M 21,0 M
P/E ratio 2022 19,1x
Yield 2022 2,37%
Capitalization 37 415 M 5 954 M 5 946 M
EV / Sales 2021 2,39x
EV / Sales 2022 2,11x
Nbr of Employees 5 551
Free-Float 30,7%
More Financials
Company
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as AlzheimerÔÇÖs disease, Bipolar disorder, depression, epilepsy, HuntingtonÔÇÖs disease, ParkinsonÔÇÖs disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression... 
Sector
Pharmaceuticals
Calendar
08/18Earnings Release
More about the company
Ratings of H. Lundbeck A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about H. LUNDBECK A/S
07/22H LUNDBECK A/S : What do you mean brain health?
PU
07/01Denovo Biopharma LLC Announces In-Licenses Late-Stage Alzheimer's Disease Ass..
CI
06/15#1VOICESUMMIT : Partnering with the advocacy community to further brain health a..
PU
06/11H LUNDBECK A/S : Lundbeck CEO, Deborah Dunsire, warns that we could be on the br..
PU
05/31H LUNDBECK A/S : Interpretation Of The Term "export" In The Indian Patent Contex..
AQ
05/26H LUNDBECK A/S : Transactions with shares and linked securities in H. Lundbeck A..
AQ
05/24H LUNDBECK A/S : The Hunt for a New Weapon Against Schizophrenia
PU
05/20Verantos and Lundbeck Announce Partnership for Migraine Care Implementing Adv..
CI
05/11H LUNDBECK A/S : Lundbeck delivers a solid EBIT of DKK 882 million and Vyepti is..
AQ
05/11H. Lundbeck A/S Provides Revenue Guidance for the Full Year of Fiscal 2021
CI
05/11H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31..
CI
05/03H LUNDBECK A/S : Lundbeck - New study finds that vortioxetine helps patients wit..
AQ
05/03H LUNDBECK A/S : Lundbeck Drug Improves Symptoms in People With Major Depressive..
MT
05/03H LUNDBECK A/S : New study finds that vortioxetine helps patients with MDD and c..
AQ
05/02H. Lundbeck A/S Announces New Study Finds That Vortioxetine Helps Patients wi..
CI
More news
News in other languages on H. LUNDBECK A/S
05/12MSCI streicht Hochtief-Aktie aus Deutschland-Index
05/11STOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
05/06ÜBERBLICK/Anstehende Indexänderungen
04/13H. LUNDBECK A/S : coup d'arrêt
03/22ÜBERBLICK/Anstehende Indexänderungen
More news
Analyst Recommendations on H. LUNDBECK A/S
More recommendations
Chart H. LUNDBECK A/S
Duration : Period :
H. Lundbeck A/S Technical Analysis Chart | LUN | DK0010287234 | MarketScreener
Technical analysis trends H. LUNDBECK A/S
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 188,30 DKK
Average target price 240,93 DKK
Spread / Average Target 28,0%
EPS Revisions
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
Anders G÷tzsche Chief Financial Officer & Executive Vice President
Lars S°ren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
H. LUNDBECK A/S-8.98%5 996
JOHNSON & JOHNSON9.21%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.13.58%234 040
NOVARTIS AG-0.17%221 954
ELI LILLY AND COMPANY44.05%221 084